Hana Biosciences (AMEX: HBX), a biopharmaceutical company that acquires, develops, and commercializes innovative products to advance cancer care, today reported its third quarter 2005 results. The company had a net loss of $1.71 million, or $0.09 per share for the quarter ended Sept. 30, 2005, compared to a net loss of $1.68 million, or $0.16 per share, in the corresponding period of the previous year. The company ended the third quarter 2005 with $5.8 million in cash and cash equivalents, compared to $6.6 million at the end of 2004. Increased investment in research and development, driven by the accelerated clinical development of its three product candidates, resulted in the additional use of funds.
